Article
Gastroenterology & Hepatology
Maria T. Abreu, David S. Rowbotham, Silvio Danese, William J. Sandborn, Ye Miao, Hongyan Zhang, Ilia Tikhonov, Remo Panaccione, Tadakazu Hisamatsu, Ellen J. Scherl, Rupert W. Leong, Ramesh P. Arasaradnam, Waqqas Afif, Laurent Peyrin-Biroulet, Bruce E. Sands, Colleen Marano
Summary: The study confirms the efficacy of ustekinumab in treating patients with ulcerative colitis for up to 3 years, and no new safety issues were observed.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Dermatology
Goncagul Babuna Kobaner, Algun Polat Ekinci, Armagan Kutlay
Summary: This study evaluated the long-term efficacy and safety of ustekinumab therapy for moderate-to-severe chronic plaque psoriasis in Turkey. Results showed high response rates and good tolerability, suggesting ustekinumab as an effective and safe treatment option for long-term management of psoriasis.
DERMATOLOGIC THERAPY
(2021)
Article
Gastroenterology & Hepatology
Maria Chaparro, Iria Baston-Rey, Estela Fernandez-Salgado, Javier Gonzalez Garcia, Laura Ramos, Maria Teresa Diz-Lois Palomares, Federico Arguelles-Arias, Eva Iglesias Flores, Mercedes Cabello, Saioa Rubio Iturria, Andrea Nunez Ortiz, Mara Charro, Daniel Ginard, Carmen Duenas Sadornil, Olga Merino Ochoa, David Busquets, Eduardo Iyo, Ana Gutierrez Casbas, Patricia Ramirez de la Piscina, Marta Maia Bosca-Watts, Maite Arroyo, Maria Jose Garcia, Esther Hinojosa, Jordi Gordillo, Pilar Martinez Montiel, Benito Velayos Jimenez, Cristina Quilez Ivorra, Juan Maria Vazquez Moron, Jose Maria Huguet, Yago Gonzalez-Lama, Ana Isabel Munagorri Santos, Victor Manuel Amo, Maria Dolores Martin-Arranz, Fernando Bermejo, Jesus Martinez Cadilla, Cristina Rubin de Celix, Paola Fradejas Salazar, Antonio Lopez San Roman, Nuria Jimenez, Santiago Garcia Lopez, Anna Figuerola, Itxaso Jimenez, Francisco Jose Martinez Cerezo, Carlos Taxonera, Pilar Varela, Ruth de Francisco, David Monfort, Gema Molina Arriero, Alejandro Hernandez Camba, Francisco Javier Garcia-Alonso, Manuel Van Domselaar, Ramon Pajares Villarroya, Alejandro Nunez, Francisco Rodriguez Moranta, Ignacio Marin-Jimenez, Virginia Robles Alonso, Maria del Mar Martin Rodriguez, Patricia Camo-Monterde, Ivan Garcia Tercero, Mercedes Navarro Llavat, Lara Arias Garcia, Daniel Hervias Cruz, Sara Sulleiro, Cynthia Novella, Eugenia Vispo, Manuel Barreiro-de Acosta, Javier P. Gisbert
Summary: This large retrospective study demonstrates the effectiveness and safety of ustekinumab as a short- and long-term treatment option for patients with Crohn's disease in real-world clinical practice, including those with refractory disease.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Immunology
William T. Connell, Julie Hong, Wilson Liao
Summary: Genetic factors, including rs35569429 and HLA-C*06:02, are associated with the response to ustekinumab therapy in psoriasis. The presence of the deletion allele of rs35569429 and being HLA-C*06:02 negative are associated with a lower treatment response rate.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Dermatology
K. B. Gordon, M. Lebwohl, K. A. Papp, H. Bachelez, J. J. Wu, R. G. Langley, A. Blauvelt, B. Kaplan, M. Shah, Y. Zhao, R. Sinvhal, K. Reich
Summary: The study found that Risankizumab demonstrated a favorable safety profile in patients with moderate-to-severe plaque psoriasis over both short-term and long-term treatment periods, with no increase in adverse event rates with long-term treatment.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Pepijn W. A. Thomas, Mark van Caem, Rachel L. West, Maurice G. V. M. Russel, Jeroen M. Jansen, Tessa E. H. Romkens, Frank Hoentjen
Summary: This study aimed to evaluate the effectiveness and safety of ustekinumab in treating Crohn's disease beyond 52 weeks. The results showed that more than half of the patients continued using ustekinumab after 104 weeks and one-third achieved corticosteroid-free clinical remission.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Rahul S. Dalal, Jordan C. Pruce, Jessica R. Allegretti
Summary: In this retrospective cohort study, we demonstrated that dose intensification of ustekinumab to every 4 or every 6 weeks was effective in both achieving and maintaining clinical remission for >40% of inflammatory bowel disease patients for up to 24 months.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Dermatology
Elzbieta Halina Klujszo, Dorota Zarebska-Michaluk, Beata Krecisz, Anna Witkowska
Summary: Biological therapies used in psoriasis treatment such as Ustekinumab (UST) pose a risk of reactivating hepatitis B virus (HBV) infection. However, observations suggest that UST therapy is a safe option for patients with resolved HBV infection, as there were no signs of HBV reactivation in the studied patients.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Katerina Bakirtzi, Elena Sotiriou, Ilias Papadimitriou, Nikolaos Sideris, Efstratios Vakirlis, Aimilios Lallas, Foteini Vrani, Demetrios Ioannides
Summary: This study evaluated the efficacy and safety of biologicals and apremilast in elderly psoriatic patients. The results showed that biologicals and apremilast have adequate efficacy in this patient population, and the incidence and severity of reported adverse events are similar to those in younger patients.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Medicine, General & Internal
Matteo Megna, Angelo Ruggiero, Teresa Battista, Laura Marano, Sara Cacciapuoti, Luca Potestio
Summary: This study investigated the long-term efficacy and safety of risankizumab for the management of moderate to severe psoriasis. The results showed significant reduction in psoriasis severity scores from week 16 and maintained up to week 104, with no serious adverse events reported.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Dermatology
Piergiorgio Malagoli, Paolo Dapavo, Giulia Pavia, Fabrizio Amoruso, Giuseppe Argenziano, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Giovanni Damiani, Valentina Dini, Giampiero Girolomoni, Claudio Guarneri, Francesco Loconsole, Alessandra Narcisi, Francesca Sampogna, Massimo Travaglini, Antonio Costanzo
Summary: Psoriasis is a common inflammatory skin disease that significantly impacts patients' quality of life. Ixekizumab, an effective and safe treatment, has been proven in clinical trials. By inhibiting inflammation, Ixekizumab can improve the clinical condition of psoriasis.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Giulia Radi, Anna Campanati, Federico Diotallevi, Giulio Rizzetto, Emanuela Martina, Ivan Bobyr, Melania Giannoni, Annamaria Offidani
Summary: The study aimed to report the efficacy and safety results of apremilast in clinical practice for patients with moderate-to-severe plaque psoriasis, showing that about half of the patients achieved good efficacy after 24 and 52 weeks of treatment, and 60% of patients reached and maintained DLQI 0-1 levels from week 24 to week 52.
DERMATOLOGIC THERAPY
(2021)
Article
Dermatology
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini, Martina Burlando, Carlo G. Carrera, Andrea Chiricozzi, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Francesca Maria Gaiani, Marco Galluzzo, Claudia Giofre, Claudio Guarneri, Francesco Loconsole, Giovanna Malara, Lorenzo Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo, Alessandra Narcisi
Summary: This retrospective study on 233 patients with moderate-to-severe plaque psoriasis who had an inadequate response to ustekinumab showed that guselkumab was more effective in achieving PASI 75/90/100 compared to ustekinumab.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Axel Svedbom, Lotus Mallbris, Per Larsson, Pernilla Nikamo, Katarina Wolk, Petra Kjellman, Eniko Sonkoly, Liv Eidsmo, Ulla Lindqvist, Mona Stahle
Summary: This study found that clinical characteristics and activating genes in the IL-23 pathway are significantly associated with the clinical course of psoriasis, and joint pain and peripheral enthesitis may indicate the probability of PsA. Patients within those categories merit specialist referral and closer follow-up. The possibility of modifying the disease course with early systemic intervention should be tested.
Article
Dermatology
Melis Gonulal, Didem Didar Balci, Aylin Ozturk, Sinan Dogan
Summary: This study investigated the long-term clinical experience with ustekinumab in psoriasis cases. It was found that ustekinumab was effective for non-naive and resistant patients. Male patients showed more rapid and robust responses to the drug, and patients were more willing to continue the treatment.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)